Pulmonx Q4 2023 GAAP EPS $(0.36) Beats $(0.42) Estimate, Sales $19.28M Beat $18.27M Estimate
Portfolio Pulse from Benzinga Newsdesk
Pulmonx (NASDAQ:LUNG) reported Q4 2023 earnings with a smaller loss per share of $(0.36) compared to the expected $(0.42), and sales of $19.28M, surpassing the $18.27M estimate. This represents a 5.26% improvement in losses and a 24.98% increase in sales year-over-year.
February 21, 2024 | 9:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pulmonx reported a smaller than expected quarterly loss and higher sales, indicating a positive trend in its financial performance.
Pulmonx's better-than-expected quarterly results, with a smaller loss per share and higher sales, suggest a positive outlook for the company. This performance, especially the year-over-year sales growth of nearly 25%, could lead to increased investor confidence and potentially a short-term uptick in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100